News

Munich neurologist wins Barancik Prize for MS research

Mikael Simons, MD, a neurologist at Technical University Munich, has been awarded this year’s $125,000 Barancik Prize for his extensive research on myelin, a protective coating that sheathes nerve cells and becomes damaged in multiple sclerosis (MS). Run by the National MS Society and funded by the Charles…

Cognition improves, other MS symptoms ease with acupuncture

A three-month course of acupuncture was associated with gains in certain aspects of cognition for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial. The traditional Chinese medicine was also linked to less fatigue, improved sleep, and reductions in certain psychological problems such as depression. The findings…

ECTRIMS, EBMT suggest stem cell transplant for some with RRMS

Stem cell transplant can be considered a viable treatment option for people with relapsing-remitting multiple sclerosis (MS) who are young, early in the disease course, do not have other major health issues, and have failed to respond to available medications, according to a new set of recommendations. The procedure…

New immune biomarkers uncovered with foralumab treatment

Intranasal foralumab can modulate a number of immune cell types in people with nonactive secondary progressive multiple sclerosis (SPMS), a study showed, revealing new immune biomarkers that show how the therapy exerts its effects in people with the condition. After three months of treatment, gene activity data showed that…

New website offers information for MS caregivers

A new website aims to provide support to caregivers of people with multiple sclerosis (MS). The site, MS Care Partner Connection, brings together information on how caregivers can care for themselves while tending to those living with the disease, how to navigate the healthcare system, and how to…

TG developing under-the-skin version of MS therapy Briumvi

TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi (ublituximab-xiiy), its approved therapy for relapsing forms of multiple sclerosis (MS). The company said it plans to start a pivotal clinical program this year which could support an application seeking approval of the…

Menopause may accelerate the progression of MS: Study

For women with multiple sclerosis (MS), disability starts to worsen significantly faster after menopause, according to a new study. “The study shows that menopause represents a unique factor in MS progression, even when we take into consideration the effects of aging,” Riley Bove, MD, study co-author at the University…

IRX4204 promotes myelin repair, improves gait in MS mouse model

IRX4204, a compound that Io Therapeutics is developing to treat neurological diseases, facilitated myelin repair and improved walking abilities in a mouse model of multiple sclerosis (MS) in a recent study, scientists report. “Our findings support the therapeutic potential of IRX4204 to promote functional neurologic recovery in…

Long-term Tecfidera slows MS disability progression in large trial

Treatment with Tecfidera (dimethyl fumarate) significantly reduces relapse rates for people with multiple sclerosis (MS), and most MS patients on the approved therapy remain free from disability progression for several years. That’s according to a final analysis from the Phase 4 ESTEEM clinical trial (NCT02047097), which tracked…

MS treatments don’t raise miscarriage, birth defect risk: Study

Most treatments for multiple sclerosis (MS) don’t increase the risk of major problems when used during pregnancy, an analysis showed. “We found that most therapies were not associated with an increased risk of miscarriage, premature birth or major birth defects,” Kerstin Hellwig, MD, study co-author and MS specialist at…

Top 10 MS news stories of 2024

The team at Multiple Sclerosis News Today has brought our audience the latest news about treatments, scientific research, and clinical trials in multiple sclerosis (MS) throughout 2024. Here is a list of the top 10 most-read articles we published this year. We look forward to continuing to serve…

Men who started on high-efficacy DMTs had fewer relapses: Analysis

Men with multiple sclerosis (MS) who started on high-efficacy disease-modifying therapies (DMTs) experienced significantly fewer relapses than those who started with moderate-efficacy DMTs, according to real-world claims analysis involving more than 10,000 U.S. patients. “No significant difference in relapse was found among females,” researchers wrote. “This observation highlights…

Exercise in MS eases fatigue, improves muscular fitness: Analysis

Exercise effectively reduces fatigue and improves muscular fitness in people with multiple sclerosis (MS), though the optimal exercise type and dose differ for each outcome, according to a meta-analysis of published studies involving more than 3,500 patients. Mind-body exercise, which combines physical movement, mental focus, and controlled breathing, was…